Ovid Therapeutics (OVID) Financials

Ovid Therapeutics (NASDAQ: OVID) continues to look like a cash-rich biotech with no commercial revenue base, but the quarter-to-quarter trend shows a business still heavily dependent on financing and investment income to fund operations. In Q1 2026, the company reported no revenue, an operating loss of $17.8 million, and a net loss of $17.0 million. That’s broadly in line with the company’s historical profile: small or inconsistent collaboration revenue, persistent operating losses, and a balance sheet that matters more than earnings right now.

The biggest positive is liquidity. Ovid ended Q1 2026 with $94.1 million in cash and equivalents and $61.5 million in short-term investments, plus $52.0 million in long-term investments. Total assets were $225.6 million versus $27.4 million in total liabilities, leaving the company with $198.3 million in equity. For a development-stage biotech, that gives Ovid meaningful runway.

Cash burn remains the key issue. Operating cash flow was negative $13.9 million in Q1 2026, and the business has posted negative operating cash flow in most recent quarters. While financing activity added cash in the quarter, the core operations are still consuming capital rather than generating it.

Compared with 2024, the balance sheet is smaller but still stronger than the near-term liability burden. At Q1 2024, Ovid had $131.6 million in assets and $78.3 million in equity. By Q1 2026, assets had declined to $225.6 million from a much higher cash position in late 2024, but liabilities stayed relatively modest. The company has clearly used capital over time, yet it still has a cushion.

Revenue remains extremely limited and volatile. Quarterly revenue over the period shown was mostly immaterial:

• Q2 2025 revenue was $6.3 million, a notable one-quarter spike.
• Most other quarters ranged from roughly $76,000 to $718,000.
• Q1 2026 revenue was $0, underscoring the lack of a stable commercial base.

Expense discipline has improved somewhat versus the higher-spend periods in 2024, but losses are still substantial. In Q1 2026, R&D was $11.2 million and SG&A was $6.7 million. Earlier periods often showed combined operating expenses above $20 million, so the current run-rate is lower, but it still exceeds revenue by a wide margin.

Other income has been an important swing factor. In some quarters, Ovid generated sizable investment-related gains or other income that reduced losses or even created quarterly net income. For example, Q4 2025 showed $21.96 million in other income and a reported net profit. But that’s not a durable operating improvement; it’s mostly tied to portfolio/investment activity and accounting noise rather than the core business.

Shareholders should also note dilution risk. The company issued $62.2 million of common equity in Q1 2026 and had 136.2 million basic shares outstanding, up from about 71 million in the 2024-2025 period. That indicates Ovid has relied on equity financing to support operations, which can pressure per-share value over time.

• Ovid ended Q1 2026 with a strong liquidity position, including $155.5 million in cash and short- and long-term investments.
• Total liabilities were only $27.4 million, leaving the company with a sizable equity cushion.
• Operating expense levels are lower than the highest-spend quarters seen in 2024, suggesting some cost control.
• The company’s investment portfolio can still contribute meaningful non-operating income in certain quarters.
• Revenue remains inconsistent and generally immaterial from quarter to quarter.
• A large part of reported profitability appears driven by other income and investment gains rather than operations.
• Q1 2026 revenue was $0, reinforcing the lack of a commercialized product base.
• Q1 2026 operating cash flow was negative $13.9 million, showing continued cash burn.
• The company issued a significant amount of equity, increasing dilution risk for existing shareholders.
• Retained earnings remain deeply negative at -$338.7 million, reflecting years of cumulative losses.

Bottom line: Ovid Therapeutics currently looks like a well-capitalized but unprofitable biotech. The balance sheet gives it time, but the company still needs a clear clinical or commercial catalyst to turn its cash position into long-term shareholder value. Until then, investors should expect continued losses, periodic financing activity, and volatility in reported quarterly results.